FibroBiologics Secures Australian Patent Acceptance for Fibroblast-Based Spinal Disc Regeneration Method

A Notice of Acceptance from IP Australia for Application No. 2024200985 positions FibroBiologics to extend enforceable IP around its fibroblast-based disc regeneration platform into a jurisdiction that carries weight in Asia-Pacific regulatory and licensing conversations. The acceptance, issued for claims covering methods of combining fibroblasts, platelet rich plasma, and nucleus pulposus conditioned media to regenerate chondrocytes and cartilage in degenerated spinal discs, follows a European grant covering platelet rich plasma conditioned fibroblasts by only weeks.

Under Australian patent procedure, a Notice of Acceptance is the functional equivalent of a notice of allowance: IP Australia has completed substantive examination, and formal grant proceeds after publication. The accepted claims cover two distinct method categories: generating chondrocytes or chondrocyte-like cells by delivering nucleus pulposus components alongside a fibroblast-and-PRP composition incorporating TGF-beta-1, notochordal cells, collagen fibrils, proteoglycans, and aggrecan; and improving the condition of an aged disc using a cell blend that mirrors the cellular composition of a non-degenerated disc, with optional supplementation by stem cells, adipocytes, or notochordal cells.

The biological rationale embedded in the claims is relevant to manufacturing and process development teams beginning to scope cell therapy scale-up. Intervertebral disc degeneration is characterised by a decline in nucleus pulposus cell populations, reduced proteoglycan and collagen matrix production, and progressive loss of disc hydration and height. The accepted methods are designed to reconstitute that cellular and biochemical environment rather than manage downstream symptoms, which means any future commercial process will need to maintain the viability and functional activity of multiple cell types and conditioned media components through fill-finish and delivery.

For regulatory affairs leads tracking the regenerative medicine IP landscape, the back-to-back geographic grants signal that FibroBiologics is building a coordinated multi-jurisdictional filing strategy around its fibroblast platform, now comprising more than 270 issued and pending patents. Australia's Therapeutic Goods Administration pathway for cell and tissue therapies, combined with enforceable local IP, creates a more defined framework for potential future licensing or manufacturing partnerships in the region.

The pace at which granted claims accumulate across Europe and Australia will be a measurable indicator of how quickly the company can establish freedom-to-operate in markets where cell therapy manufacturing infrastructure is expanding.

Source: FibroBiologics, Inc. via PR Newswire, 14 October 2026.